DexCom (DXCM) Getting Positive Press Coverage, Analysis Finds

News headlines about DexCom (NASDAQ:DXCM) have been trending positive on Tuesday, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. DexCom earned a media sentiment score of 0.30 on Accern’s scale. Accern also gave news coverage about the medical device company an impact score of 87 out of 100, meaning that recent news coverage is very likely to have an impact on the stock’s share price in the near future.

Here are some of the news articles that may have effected Accern’s analysis:

A number of brokerages have weighed in on DXCM. Cowen and Company reiterated an “outperform” rating and issued a $90.00 price objective on shares of DexCom in a research report on Tuesday, April 18th. BTIG Research downgraded shares of DexCom from a “buy” rating to a “neutral” rating in a research report on Wednesday, May 3rd. William Blair restated an “outperform” rating on shares of DexCom in a research report on Thursday, April 27th. Jefferies Group LLC dropped their price objective on shares of DexCom to $91.00 and set a “buy” rating for the company in a research note on Tuesday, May 9th. Finally, Canaccord Genuity dropped their price objective on shares of DexCom from $95.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday, May 3rd. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $89.47.

DexCom (NASDAQ DXCM) opened at 70.69 on Tuesday. The company has a 50 day moving average of $71.68 and a 200-day moving average of $74.65. DexCom has a 52-week low of $57.68 and a 52-week high of $96.38. The stock’s market capitalization is $6.11 billion.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Tuesday, May 2nd. The medical device company reported ($0.49) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.55) by $0.06. The company had revenue of $142.30 million during the quarter, compared to analysts’ expectations of $143.94 million. DexCom had a negative return on equity of 32.94% and a negative net margin of 14.70%. Equities research analysts anticipate that DexCom will post ($0.71) EPS for the current year.

In other news, CEO Kevin R. Sayer sold 8,649 shares of DexCom stock in a transaction dated Wednesday, May 17th. The stock was sold at an average price of $68.39, for a total transaction of $591,505.11. Following the transaction, the chief executive officer now owns 347,329 shares in the company, valued at approximately $23,753,830.31. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Terrance H. Gregg sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, April 20th. The shares were sold at an average price of $74.10, for a total value of $1,111,500.00. Following the completion of the sale, the insider now owns 454,559 shares in the company, valued at approximately $33,682,821.90. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 53,063 shares of company stock valued at $3,800,519. 1.70% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Stock Observer and is the sole property of of Stock Observer. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with's FREE daily email newsletter.

Leave a Reply